Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development
Omri Wolk, Riad Agbaria, Arik Dahan Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Abstract: The main objective of this work was to investigate in-silico predictions of physicochemical properties, in order t...
Saved in:
Main Authors: | Wolk O (Author), Agbaria R (Author), Dahan A (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pediatric Biopharmaceutical Classification Systems (pBCS)
by: Justyna Srebro, et al.
Published: (2023) -
Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System
by: Jose-Manuel de, et al.
Published: (2019) -
Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
by: Konstantinos Stamatopoulos, et al.
Published: (2023) -
Biopharmaceutics classification system (BCS)-based biowaiver for immediate release solid oral dosage forms of moxifloxacin hydrochloride (Moxiflox GPO) manufactured by the Government Pharmaceutical Organization (GPO)
by: Nawaphon Saelim, et al.
Published: (2016) -
In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug
by: Isabel Gonzalez-Alvarez, et al.
Published: (2024)